IP Library › Assignment 023031/0963
Patent Assignment
Reel/Frame 023031/0963

Assignment of Assignor's Interest

Recorded: 2009-07-27 Received: 2009-07-30 Pages: 20
Assignor
BAYER PHARMACEUTICALS CORPORATION
Executed: 2007-12-19
Assignee
BAYER HEALTHCARE LLC
555 WHITE PLAINS ROAD, TARRYTOWN, NY, USA 10591, UNITED STATES
Covered Properties (65)
Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer
Application: 11/579,093 →
Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Application: 11/956,111 →
Aryl Ureas with Angiogenisis Inhibiting Activity
Application: 11/932,626 →
Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas
Application: 11/932,397 →
Inhibition of P38 Kinase Activity Using Substituted Heterocyclic Ureas
Application: 11/932,548 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinease Inhibitors
Application: 11/845,595 →
Omega-Carboxy Aryl Substituted Diphenyl Ureas as P38 Kinase Inhibitors
Application: 11/845,597 →
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors
Application: 11/775,457 →
Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
Application: 11/768,533 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application: 11/768,104 →
Inhibition of Raf Kinase Using Substituted Heterocyclic Ureas
Application: 11/768,112 →
Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
Treatment of Cancers with Acquired Resistance to Kit Inhibitors
Application: 60/885,728 →
Treatment of Cancers Having Resistance to Chemotherapeutic Agents
Application: 60/885,731 →
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
Application: 11/598,824 →
Treatment of Cancers Having Resistance to Chemotherapeutic Agents
Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
Methods for Prognosis and Monitoring Cancer Therapy
Application: 11/589,295 →
Diaryl Ureas with Kinase Inhibiting Activity
Application: 10/571,100 →
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
Application: 11/480,360 →
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
Application: 10/581,125 →
Immunohistochemical Methods
Application: 10/576,733 →
Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
Pharmaceutical compositions for the treatment of cancer
Application: 11/212,907 →
Pharmaceutical compositions for the treatment of hyper-proliferative disorders
Application: 11/212,109 →
Inhibition of Raf Kinase Using Quinolyl, Isoquinolyl or Pyridyl Ureas
Application: 11/158,048 →
Raf kinase inhibitors
Application: 11/149,332 →
Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions
Application: 10/895,985 →
Diaryl ureas for diseases mediated by PDGFR
Application: 10/848,567 →
Novel Bicyclic Urea Derivatives Useful in the Treatment of Cancer and Other Disorders
Application: 10/788,426 →
Substituted Pyridine Derivatives Useful in the Treatment of Cancer and Other Disorders
Application: 10/789,446 →
2-Oxo-1,3,5-Perhydrotriazapine Derivatives Useful in the Treatment of Hyper-Proliferative, Angiogenesis, and Inflammatory Disorders
Application: 10/788,405 →
Novel Cyanopyridine Derivatives Useful in the Treatment of Cancer and Other Disorders
Application: 10/788,029 →
Methods for prediction and prognosis of cancer, and monitoring cancer therapy
Application: 10/675,406 →
Fluoro substituted omega-carboxyaryl diphenyl urea, its salts, prodrugs, and metabolites, for the treatment of cancer and other proliferative disorders
Application: 60/489,102 →
Aryl Ureas with Angiogenisis Inhibiting Activity
Application: 10/361,858 →
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors
Application: 10/361,850 →
Aryl ureas with raf kinase and angiogenisis inhibiting activity
Application: 10/361,844 →
Pyridine, Quinoline, and Isoquinoline N-Oxides as Kinase Inhibitors
Aryl Ureas as Kinase Inhibitors
Application: 10/361,859 →
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
Application: 10/308,187 →
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application: 10/283,248 →
Inhibition of Raf Kinase Using Quinolyl, Isoquinolyl or Pyridyl Ureas
Application: 10/125,369 →
Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
Application: 10/086,417 →
Hydroxy, W-Carboxyaryl Substituted Diphenyl Ureas and Dirivatives Thereof as Raf Kinase Inhibitors
Application: 10/071,248 →
Inhibition of Raf Kinase Using Quinolyl, Isoquinolyl or Pyridyl Ureas
Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas
Application: 10/060,396 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application: 10/042,226 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application: 10/042,203 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application: 09/889,227 →
Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors
Application: 09/993,647 →
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application: 09/948,915 →
Inhibition of p38 kinase activity by aryl ureas
Application: 09/947,761 →
Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application: 09/907,970 →
Heteroaryl Ureas Containing Nitrogen Hetero-Atoms as P38 Kinase Inhibitors
Application: 09/838,286 →
Inhibition of Raf Kinase Using Quinolyl, Isoquinolyl or Pyridyl Ureas
Application: 09/777,920 →
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
Application: 09/778,039 →
omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors
Application: 09/773,675 →
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application: 09/773,604 →
Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors
Application: 09/773,658 →
Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
Application: 09/773,659 →
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application: 09/773,672 →
Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Application: 09/758,548 →
Raf kinase inhibitors
Application: 09/755,060 →